25,000 human genes
Targeted drugs approved by FDA/CFDA and recommended by NCCN guidelines
2,000+ targeted drugs for solid tumors in clinical trials
TMB MSI PD-L1 MMR
Prediction of treatment and prognostic efficacy
65 hereditary tumor susceptibility genes
27 SNP loci across 18 genes
Assessment of chemotherapy drug sensitivity and toxicity
Equipped with the Illumina NextSeq 500 sequencing system and the fully automated GeneReader NGS System (second-generation sequencing platform), our oncology NGS products cover gene mutations associated with more than 2,000 anti-tumor drugs across brain tumors, lung cancer, gastric cancer, liver cancer, ovarian cancer, colorectal cancer and melanoma, supported by automated result analysis and clinical interpretation systems. We currently offer dozens of small and large panels, including whole-exome sequencing, the 1,421-gene panel, the 430-gene panel and the 127-gene panel.
